Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $61.2352W HIGH $90.87
Volume
1.23 M
Value Traded
61.32 M
Short % Float
12.04%
-1.42%Week
-7.41%1 Month
-26.27%3 Month
-8.92%6 Month
+73.98%5 Year
+335.51%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
5.22 B
EPS (TTM)
-0.46
P/E Ratio
-
Ent. Value
3.58 B
Total Shares
83.46 M
Float Shares
80.86 M
Insiders
3.11%
Institutions
121.09%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
PTCT Catalyst Timeline
Dated clinical, regulatory and corporate events for PTC Therapeutics, Inc.
Catalyst Timeline
Dated clinical, regulatory & corporate events for PTC Therapeutics, Inc.
978Total events
3Upcoming
299Tier-1 (high impact)
2012 to 2027Coverage
Upcoming catalysts 2
Event history 50
▲AcquiredST-920Corporate
PTC completes acquisition of ST-920 from Sangamo Therapeutics
Fabry diseasesource ↗
▲Oral PresentationSEPHIENCEApprovedPresentation
AMPLIPHY study analysis: 100% greater reduction in blood Phe after switching from sapropterin
phenylketonuria (PKU)source ↗
▲Quarterly UpdateCorporate
Reported Q2 2026 financial results with total revenue of $361 million
●Development Candidate NominationPTC303Preclinical
PTC303 named as MSH3 splicing program development candidate
Huntington's disease and myotonic dystrophysource ↗
▲Topline ReadoutvotoplamClinical Data
Positive 24-month results from PIVOT-HD long-term extension study reported
Huntington's diseasesource ↗
▲Runway Guidance UpdateCorporate
Raised full-year 2026 total revenue guidance to $1.18-$1.28 billion
▲Trial InitiationVatiquinoneFiledTrial
PROVE-FA study to support NDA resubmission expected to initiate in Q3 2026
Friedreich's ataxiasource ↗
▲Trial InitiationPTC844Trial
Phase 2a study of PTC844 expected to initiate in Q3 2026
DHODH inhibitor indicationssource ↗
▲Trial InitiationPTC612Trial
Phase 1 study of PTC612 initiated
NLRP3-mediated inflammatory diseasessource ↗
▲Milestone PaymentvotoplamCorporate
$50 million milestone payment from Novartis for INVEST-HD initiation
Huntington's diseasesource ↗
◆Oral PresentationPresentation
PTC Therapeutics to present at Goldman Sachs 47th Annual Global Healthcare Conference
◆Oral PresentationPresentation
PTC Therapeutics to present at RBC Capital Markets 2026 Global Healthcare Conference
◆Oral PresentationPresentation
PTC Therapeutics to present at Bank of America Securities Health Care Conference 2026
▲Interim AnalysisvotoplamTrial
Positive topline results from 24-month interim analysis of PIVOT-HD extension study of votoplam
Huntington's diseasesource ↗
▲FDA Feedback ReceivedVatiquinoneFiledFDA Meeting
FDA feedback received supporting initiation of open-label vatiquinone registration study
Friedreich's ataxiasource ↗
▲Topline ReadoutvotoplamClinical Data
Positive topline results from 24-month interim analysis of PIVOT-HD extension study
Huntington's diseasesource ↗
▲Trial InitiationvotoplamTrial
Novartis initiated global Phase 3 INVEST-HD study
Huntington's diseasesource ↗
◆Oral PresentationvotoplamPresentation
PTC Therapeutics to host webcast to share 24-month interim analysis results from PIVOT-HD long-term extension study
Huntington's diseasesource ↗
◆Interim AnalysisvotoplamTrial
24-month interim analysis of PIVOT-HD long-term extension study
Huntington's diseasesource ↗
●Quarterly UpdateCorporate
Novartis quarterly earnings call where long-term extension data were discussed
▲Trial InitiationPTC612Trial
Phase 1 study of PTC612 initiated in Q2 2026
NLRP3-mediated inflammatory diseasessource ↗
▲Trial InitiationvotoplamTrial
INVEST-HD Phase 3 study initiated (first patient dosed) in Q2 2026
Huntington's diseasesource ↗
▲Milestone PaymentvotoplamCorporate
Received $50 million milestone payment from Novartis for INVEST-HD initiation
Huntington's diseasesource ↗
▲Product LaunchSEPHIENCEApprovedPost-Market
Global Sephience launch continues with Q1 2026 revenue of $125M, 36% QoQ growth
Phenylketonuria (PKU)source ↗
◆Timing GuidanceEvrysdiApprovedPresentation
Royalty Pharma option to purchase 50% of remaining PTC royalty until Mar 31, 2026
spinal muscular atrophysource ↗
▼NDA SubmissionTranslarnaApprovedRegulatory Filing
Withdrew NDA resubmission for Translarna
nonsense mutation Duchenne muscular dystrophysource ↗
◆Oral PresentationPresentation
CEO presentation at 44th Annual J.P. Morgan Healthcare Conference
▲Product LaunchSEPHIENCEApprovedPost-Market
Lançamento do Sephience no Japão após conclusão de discussões de preço
fenilcetonúria (PKU)source ↗
▲Quarterly UpdateCorporate
Strong cash position of approximately $1.94B as of December 31, 2025
◆Timing GuidanceEvrysdiApprovedPresentation
PTC option to sell remaining Evrysdi royalty to Royalty Pharma until Dec 31, 2025
spinal muscular atrophysource ↗
▲EU ApprovalSEPHIENCEApprovedEx-US Regulatory
Sephience aprovado no Japão pelo MHLW para PKU
fenilcetonúria (PKU)source ↗
▲Other Regulator MilestoneSEPHIENCEApprovedEx-US Regulatory
Sephience approved by MHLW in Japan for PKU
fenilcetonuria (PKU)source ↗
▲Other Regulator MilestoneSEPHIENCEApprovedEx-US Regulatory
Sephience approved by Japanese MHLW for PKU
phenylketonuria (PKU)source ↗
▲Quarterly UpdateSEPHIENCEApprovedCorporate
Sephience Q4 2025 global revenue of $92.5M
Phenylketonuria (PKU)source ↗
Past FDA Catalysts and PDUFA Decisions
How PTCT actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| 2025-08-19 | Vatiquinone | PDUFA Date CRL | PDUFA |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
C53 / 100
Pipeline Score
$645M
Pipeline Value
$4.1B
Commercial Value
Fair Value
Valuation Signal
7
Drugs Scored
0.4x
rNPV / MCap
Top 14%
Small Cap(rank 93 of 658)
Percentile Rank
PTC Therapeutics, Inc. carries a moderate pipeline score (53/100), with $993M risk-adjusted pipeline value, led by EPI-743 in Leigh Syndrome (Phase 2).
Commercial products (revenue basis: trailing 4 quarters of total revenue (10-K and 10-Q), to Jun 2026; product lines: last four quarters to Jun 2026 (10-K and 10-Q)) Revenue $1.0B x 4.1 = $4.1B
| Product | Revenue | Prior period | Change |
|---|---|---|---|
| Sephience | $387M | - | - |
| Translarna | $191M | $293M | -34.8% |
| Emflaza | $108M | $187M | -41.9% |
| Upstaza/Kebilidi | $57M | $36M | +58.4% |
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EPI-743 Small moleculeCompletedNCT02352896 | Leigh Syndrome | Phase 2 | COMPLETED | 65 | Oct 30, 2023 |
Clinical Trial Results
Readouts, endpoints and source filings for every PTCT program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| Sephience | phenylketonuria (PKU) | 2026-08-24 | 100% greater reduction in blood Phe for participants on sapropterin at screening after switching to Sephience; clinically meaningful reductions in blood Phe levels within 14 days; normalization of blood Phe levels (<120 µmol/L) in a rapid timeframeRead More | PTC Therapeutics Announces New Sephience™ (sepiapterin) Data Reinforcing Broad Patient Benefits Including Sustained Metabolic Control and Diet Liberalization as well as Consistent Favorable Safety ProfileRead More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Boulding Mark ElliottOfficer (EXEC. VP AND CLO) | Option | 435 105,707 held | $39.42 | 10/06/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in PTCT
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| RTW INVESTMENTS, LP | 5.4 % (1.9 %) | 631.88 M | 7.75 M |
PTCT Institutional Ownership Trends
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-12-18 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How PTCT ranks across every disease it competes in
Competitive Position is a premium feature
See how PTCT ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialPTCT News
PTCT▲ +5.2%on this news
PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
PTC Therapeutics has approved inducement grants for 37 new employees, including stock options and restricted stock units. The grants, totaling 51,270 stock options and 37,995 RSUs, were made under Nasdaq Listing Rule 5635(c)(4) to enhance employment offers. The stock options have a 10-year term and vest over four years, while the RSUs vest annually.
Read more →PTCTPTC Completes Acquisition of ST-920 Fabry Disease Gene Therapy
PTC Therapeutics has completed its acquisition of ST-920, a gene therapy for Fabry disease, and anticipates submitting a Biologics License Application (BLA) to the FDA by Q4 2026. This therapy aims to address the limitations of existing enzyme replacement therapies by providing a one-time treatment that promotes long-term enzyme production. The acquisition is part of PTC's strategy to enhance its portfolio of treatments for rare disorders.
Read more →PTCTPTC Therapeutics to Participate in Upcoming Investor Conferences
PTC Therapeutics, Inc. has announced its participation in several upcoming investor conferences, including the Wells Fargo 21st Annual Healthcare Conference and the Morgan Stanley 24th Annual Global Healthcare Conference. Executives will present key insights on the company's pipeline and strategies. The presentations will be available via live webcast and archived for future access.
Read more →PTCTPTC Therapeutics Announces New Sephience™ (sepiapterin) Data Reinforcing Broad Patient Benefits Including Sustained Metabolic Control and Diet Liberalization as well as Consistent Favorable Safety Profile
PTC Therapeutics announced new data on Sephience (sepiapterin) at the SSIEM Symposium, highlighting its effectiveness in achieving significant diet liberalization and maintaining target blood phenylalanine levels in patients with phenylketonuria (PKU). The data also reinforced a favorable safety profile and demonstrated benefits across various patient subgroups. The findings support the potential of Sephience to improve the quality of life for individuals affected by PKU.
Read more →PTCTPTC to Expand Rare Disease Portfolio with Acquisition of BLA-Stage ST-920 Fabry Disease Program
PTC Therapeutics plans to acquire the ST-920 program, which is a one-time AAV gene therapy for Fabry disease. This acquisition aims to enhance PTC's rare disease portfolio by leveraging its existing regulatory and commercial infrastructure. ST-920 has demonstrated long-term clinical benefits and safety, aligning with PTC's expertise in Fabry therapy commercialization.
Read more →PTCT▼ -9.9%on this news
PTC Therapeutics Provides Corporate Update and Reports Second Quarter 2026 Financial Results
PTC Therapeutics reported robust financial results for Q2 2026, with total revenue reaching $361 million. The company raised its full-year revenue guidance to between $1.18 and $1.28 billion, driven by strong sales of Sephience™. Additionally, PTC made significant advancements in its R&D pipeline, including the initiation of new clinical studies. However, challenges remain, particularly with generic competition affecting some product revenues.
Read more →PTCTPTC Therapeutics to Report Second Quarter 2026 Financial Results on Thursday, July 30, 2026
PTC Therapeutics, Inc. will hold a webcast conference call on July 30, 2026, to report its second quarter financial results and discuss its business outlook. The event will be accessible via the company's website, with a replay available for 30 days. PTC focuses on developing treatments for rare disorders.
Read more →PTCT▲ +7.2%on this news
PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that on June 11, 2026, the company approved non-statutory stock options to purchase an...
PTC Therapeutics, Inc. has announced the approval of non-statutory stock options and restricted stock units as inducement grants for 18 new employees. This decision was made in accordance with the Nasdaq Listing Rule 5635(c)(4) on June 11, 2026. The stock options have an exercise price of $74.71, with a 10-year term and a vesting schedule of four years. This initiative aims to enhance the company's ability to attract and retain skilled professionals in a competitive market.
Read more →PTCTPTC Therapeutics Announces Pricing of Convertible Notes Offering to Refinance 2026 Convertible Notes
PTC Therapeutics has announced a $500 million offering of 0% Convertible Senior Notes due 2031 to refinance its 2026 convertible notes. The offering is expected to close on June 18, 2026, and the proceeds will primarily be used to repurchase existing notes. The conversion price is set at a 40% premium over the current stock price, indicating a strategic financial maneuver.
Read more →PTCTPTC Therapeutics Announces Proposed Convertible Notes Offering to Refinance 2026 Convertible Notes
PTC Therapeutics announced a proposed offering of $500 million in Convertible Senior Notes due 2031 to refinance its existing 2026 convertible notes. The proceeds will be used for repurchasing or repaying the 2026 notes and for share buybacks. The offering is subject to market conditions, and the terms will be finalized at pricing.
Read more →PTCTPTC Therapeutics Provides Corporate Update and Reports First Quarter 2026 Financial Results
PTC Therapeutics provided a corporate update along with its financial results for Q1 2026, reporting a total revenue of $273 million, which included $226 million from product sales. The company highlighted significant growth in the Sephience launch, with first quarter revenue of $125 million, reflecting a 36% increase from the previous quarter. Positive topline results from an interim analysis of the PIVOT-HD extension study for votoplam were announced, supporting ongoing studies. However, despite these successes, PTC reported a loss of $2.8 million for the quarter and faced challenges in maintaining revenue growth.
Read more →PTCT▼ -8.1%on this newsshared move
PTC Therapeutics Reports Positive Topline Results from Month 24 Interim Analysis of PIVOT-HD Extension Study of Votoplam
PTC Therapeutics announced positive topline results from the 24-month interim analysis of the PIVOT-HD extension study, showing a dose-dependent benefit in slowing disease progression in Stage 2 Huntington's disease patients. The study demonstrated a 52% slowing at the 10 mg dose compared to a natural history cohort. The favorable safety profile was also maintained, supporting the ongoing Phase 3 INVEST-HD study initiated by Novartis.
Read more →PTCTPTC Therapeutics to Report Results from PIVOT-HD Long Term Extension Study
PTC Therapeutics will present results from the 24-month interim analysis of the PIVOT-HD long-term extension study for votoplam. The data supports the ongoing Phase 3 INVEST-HD study, with Novartis evaluating next steps, including potential FDA actions. The study aims to assess the safety and efficacy of votoplam in Huntington's disease patients.
Read more →PTCTPTC Therapeutics to Report First Quarter 2026 Financial Results on Thursday, May 7, 2026
PTC Therapeutics, Inc. will host a webcast on May 7, 2026, to report its first quarter financial results. The call will also provide updates on the company's business strategies and outlook. Interested parties can access the live webcast through the company's website, with a replay available for 30 days post-event.
Read more →PTCTPTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that on April 13, 2026, the company approved non-statutory stock options to purchase an...
PTC Therapeutics, Inc. announced the approval of non-statutory stock options and restricted stock units for a new non-executive employee as part of their employment compensation. The awards, totaling 1,155 stock options and 925 RSUs, were approved by the Compensation Committee under Nasdaq Listing Rule 5635(c)(4). The stock options have an exercise price of $70.42 and will vest over a four-year period. This strategy is part of PTC's efforts to entice new talent to the company.
Read more →PTCTPTC Therapeutics Appoints Biotech Banking Pioneer Jessica Chutter to Board of Directors
PTC Therapeutics has appointed Jessica Chutter to its Board of Directors. Chutter, a pioneer in biotechnology investment banking, has a notable career at Morgan Stanley, where she led significant capital raising and strategic transactions. Her experience is expected to aid PTC in its growth and strategic initiatives.
Read more →PTCTPTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that on March 10, 2026, the company approved non-statutory stock options to purchase an...
PTC Therapeutics, Inc. has announced the approval of non-statutory stock options and restricted stock units for 18 new employees, totaling 14,550 stock options and 17,515 RSUs. These inducement grants were issued in accordance with Nasdaq Listing Rule 5635(c)(4) as part of the new hires' employment compensation. The options have an exercise price of $68.56 and a vesting schedule spanning four years, contingent upon continued employment. This initiative demonstrates PTC's commitment to attract talent and bolster its workforce.
Read more →PTCTPTC Therapeutics to Participate at Upcoming Investor Conferences
PTC Therapeutics, Inc. announced its participation in several upcoming investor conferences, including the TD Cowen 46th Annual Health Care Conference and the Barclays Global Healthcare Conference. Executives will present on March 2, March 10, and March 11, with live webcasts available for investors. The company emphasizes its mission to develop treatments for rare disorders.
Read more →About PTC Therapeutics, Inc.
Headquarters500 WARREN CORPORATE CENTER DRIVE, WARREN, NJ, 07059
BIOPHARMAWATCH ELITE PLUS
Trade the next PTCT catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime